MRX CEO Ian Lowitt Sells Shares Worth $2.32 Million

Ian Lowitt, CEO of MRX, sold 37,143 shares in a planned transaction.

Written by EarningsIQ · Published Jun 16, 2026, 5:03 PM EDT

Key Points

Ian Lowitt, CEO of MRX, sold 37,143 shares on June 12, 2026, for about $2.32 million.
Shares of MRX traded near $62.50, with notable institutional activity including BlackRock and FMR LLC.
Analysts like TD Cowen and Barclays maintain 'buy' ratings with targets up to $75.00.

Ian Lowitt, the Chief Executive Officer of MRX, sold 37,143 shares of the company on June 12, 2026. The transaction, which was planned, amounted to approximately $2.32 million, with an average sale price of $62.37 per share.

Insider Buying and Selling at MRX

Several insiders at MRX have been active recently. On June 15, 2026, Paolo Tonucci, Chief Strategist and CEO of Capital Markets, sold 16,666 shares at an average price of $62.46 per share in a planned transaction. On June 9, 2026, other insiders, including Robert Mark Pickering, Sarah Ing, John Pietrowicz, and Linda Kristine Myers, each bought 2,070 shares in unplanned transactions.

Other Institutional Activity in MRX

Institutional investors have been adjusting their positions in MRX. BlackRock, Inc. increased its holdings by 422,791 shares, bringing its total to 4,389,325 shares valued at about $195.68 million. FMR LLC made a significant addition of 2,147,113 shares, ending with 3,481,911 shares worth approximately $155.22 million. In contrast, Loomis Sayles & Co L P slightly reduced its position by 16,881 shares, holding 1,918,622 shares valued at $85.53 million.

MRX Stock Snapshot

Shares of MRX traded near $62.50. The stock has seen various institutional activities and insider transactions. Analysts continue to show interest, with several maintaining 'buy' ratings and target prices that suggest potential growth.

Analysts Set New Price Targets

Analysts remain optimistic about MRX. On June 8, 2026, TD Cowen maintained its 'buy' rating, setting a price target of $75.00. Barclays also maintained a 'buy' rating with a $60.00 target on May 11, 2026. The consensus among analysts is a 'buy' recommendation, with an average target price suggesting further upside.

Bottom Line

Ian Lowitt's recent sale of MRX shares is part of a planned transaction, reflecting personal financial management rather than a lack of confidence in the company. Institutional investors continue to show interest in MRX, with notable changes in positions. Analysts remain positive, maintaining 'buy' ratings with targets indicating potential growth. As always, these insights are based on past filings and reports and may not reflect the current market position.